Healthcare Industry News: Beckman Coulter
News Release - December 14, 2011
Interleukin Genetics Appoints Lynn Doucette-Stamm Vice President of DevelopmentWALTHAM, Mass.--(Healthcare Sales & Marketing Network)-- Interleukin Genetics, Inc. (OTCQB: ILIU.PK ) today announced the appointment of Lynn Doucette-Stamm, Ph.D., as Vice President of Development. In this role, Dr. Doucette-Stamm will supervise the operational activities of the Company’s on-going clinical studies and development of genetic tests.
“We are pleased that Lynn is joining our team in this newly created role,” said Dr. Kenneth Kornman, chief scientific officer, Interleukin Genetics, Inc. “Lynn’s breadth of experience in the genomics field and her proven track record of managing product development teams, partner relationships and overseeing profitable commercial business units will play an essential role in Interleukin Genetics’ continued growth.”
Dr. Doucette-Stamm has nearly 20 years of experience in the genomics and biotechnology industry. Most recently, she served as vice president of business development at Agencourt Bioscience and remained at the company through its acquisition by Beckman Coulter. Prior to her business development roles, Dr. Doucette-Stamm served as director of genomics and vice president and general manager of the Genome Vision Services Unit, Genome Therapeutics Corporation for more than 11 years. In this position, she was responsible for managing large teams working on the Human Genome Project as well as commercial sequencing programs and established the profitable genomics business unit that was later acquired by Agencourt. She earned a Bachelors of Science degree in biology from McMaster University, a Ph.D. in genetics from Cornell University and was part of the MIT-based global collaborative that identified the gene for Huntington’s disease.
“Interleukin Genetics is in the unusual position of having multiple genetic tests that have been validated and that provide personalized, actionable information to help people live healthier lives,” said Dr. Doucette-Stamm, vice president of Development, Interleukin Genetics, Inc. “I look forward to playing a meaningful role to help expand and develop the Company’s business.”
About Interleukin Genetics, Inc.
Interleukin Genetics, Inc. (OTCQB: ILIU.PK ) develops and markets a line of genetic tests under the Inherent Health® brand. The products empower individuals to prevent certain chronic conditions and manage their existing health and wellness through genetic-based insights with actionable guidance. Interleukin Genetics leverages its research, intellectual property and genetic panel development expertise in metabolism and inflammation to facilitate the emerging personalized healthcare market. The Company markets its tests through partnerships with health and wellness companies, healthcare professionals and other distribution channels. Interleukin Genetics’ flagship products include its proprietary PST® genetic risk panel for periodontal disease and tooth loss susceptibility sold through dentists and the Inherent Health Weight Management Genetic Test that identifies the most effective diet and exercise program for an individual based on genetics. Interleukin Genetics is headquartered in Waltham, Mass. and operates an on-site, state-of-the-art DNA testing laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). For more information, please visit http://www.ilgenetics.com.
Certain statements contained herein are “forward-looking” statements. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, those risks and uncertainties described in the Interleukin Genetics’ annual report on Form 10-K for the year ended December 31, 2010 and other filings with the Securities and Exchange Commission. Interleukin Genetics disclaims any obligation or intention to update these forward-looking statements.
Source: Interleukin Genetics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.